Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 30;13:998236. doi: 10.3389/fimmu.2022.998236

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Wang, Lu, Wang, Liu, Wu, Yang, Huan and Gong

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

(A) WB for IGFBP2 in 3 pairs patients from Nantong cohort. (B) Represented IHC for IGFBP2 in three parents with different WHO stage from Nantong cohort. (C) Boxplot of IHC for IGFBP2 in six pairs parents from Nantong cohort. (D) The expression level of IGFBP2 in glioma sample and the control normal sample. (E) Kaplan-Meier survival curve showing survival probability of high- or low-expression IGFBP2. (F) The 1-year, 2-year, 3-year, 4-year, and 5-year survival ROC curves are predicted by the expression of IGFBP2. (G) The heat map shows the correlation between IGFBP2 and eight immune checkpoints in TCGA. (H) GSEA maps of cancer and immune-related signaling pathways positively modulated by IGFBP2. ^∗∗P < 0.01; ^∗∗∗P < 0.001; ^∗∗∗∗P < 0.0001.